FDA Advisers Back Broader Humira Approval

Law360, New York (August 28, 2012, 6:45 PM EDT) -- A U.S. Food and Drug Administration advisory panel on Tuesday backed the use of Abbott Laboratories Inc.’s blockbuster anti-inflammatory drug Humira to treat the bowel disease ulcerative colitis, saying its benefits outweighed its risks, despite a recent FDA report questioning its efficacy in treating the condition.

The recommendation was passed along at a meeting of the FDA’s gastrointestinal drugs advisory committee, made up of a number of outside medical experts, which voted 15 to 2 that the expected benefits of Humira for certain patients with ulcerative...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.